Skip to main content
KPC PHARMACEUTICALS, INC. logo

KPC PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · 600422 ISIN · CNE0000015P8 LEI · 3003007ZALHXKUFMKN96 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 2,727 across all filing types
Latest filing 2016-09-01 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 600422

About KPC PHARMACEUTICALS, INC.

https://en.kpc.com.cn/

KPC Pharmaceuticals, Inc. specializes in the research, development, and manufacturing of pharmaceutical products, with a significant focus on natural and botanical medicines. The company is a global leader in the production of artemisinin-based anti-malarial treatments, including artemether and its derivatives. Its portfolio encompasses a wide range of therapeutic areas, notably cardiovascular and cerebrovascular health, where it utilizes Panax notoginseng saponins as a core component. KPC integrates traditional medicinal knowledge with modern pharmacological techniques to develop standardized botanical extracts and chemical drugs. The organization operates extensive production facilities and research centers dedicated to drug discovery and quality control. Its business activities extend to the distribution of healthcare products and the provision of medical services, aiming to provide comprehensive health solutions through innovation in natural medicine and biotechnology.

Recent filings

Filing Released Lang Actions
八届二十次董事会决议公告
Board/Management Information Classification · 95% confidence The document is a board resolution announcement from Kunming Pharmaceutical Group Co., Ltd. It details decisions made at the 20th meeting of the 8th board, including approvals for credit guarantees, investments, acquisitions, loans, and executive compensation adjustments. The document includes voting results and specifics about the board meeting but does not contain financial statements or detailed financial performance data. It is not an annual report, audit report, or earnings release. It is not a call transcript or investor presentation. The content focuses on board decisions and management matters, especially regarding executive compensation and corporate actions requiring board approval. Therefore, the document fits best under the category of Board/Management Information (MANG). The document length is short and contains substantive content about board resolutions, not just an announcement of a report publication or certification. Confidence is high due to clear identification of board meeting resolutions and voting results.
2016-09-01 Chinese
关于股东权益变动事项完成股份过户登记的更正公告
Major Shareholding Notification Classification · 95% confidence The document is a correction announcement regarding a previously disclosed shareholder equity change and share transfer registration. It corrects the number of shares transferred and clarifies the shareholding percentage. The document is short (801 characters) and focuses on correcting a prior announcement about shareholding changes, not presenting new financial data or detailed reports. This fits the category of Major Shareholding Notification (MRQ), as it deals with changes in significant share ownership levels.
2016-09-01 Chinese
关于股东权益变动事项完成股份过户登记的公告
Major Shareholding Notification Classification · 95% confidence The document is an announcement regarding the completion of share transfer registration related to changes in shareholder equity. It details the transfer of shares from one entity to another and confirms the updated shareholding structure. There is no financial data, earnings information, or detailed report content. The document is a formal notification about a change in major shareholding or shareholder structure. Therefore, it fits the category of Major Shareholding Notification (MRQ). The document length is short and focused on shareholding changes, not a full report or announcement of a report publication.
2016-08-31 Chinese
2016年半年度报告摘要
Interim / Quarterly Report Classification · 95% confidence The document is titled as a '2016 年半年度报告摘要' which translates to '2016 Half-Year Report Summary'. It contains detailed financial data for the first half of 2016, including income, profit, cash flow, segment analysis, and management discussion and analysis. The document includes comprehensive financial tables, business segment performance, shareholder information, and management commentary. The length is over 13,000 characters, indicating it is a substantive report rather than a brief announcement. The content matches the characteristics of an Interim / Quarterly Report, which provides a comprehensive financial report for a period shorter than a full fiscal year with actual financial statements and analysis. Therefore, the document should be classified as an Interim / Quarterly Report (IR). H1 2016
2016-08-17 Chinese
八届十九次董事会决议公告
Board/Management Information Classification · 95% confidence The document is a board resolution announcement from Kunming Pharmaceutical Group Co., Ltd. It details decisions made at the 19th meeting of the 8th board, including approval of the 2016 half-year report and a special report on the use of raised funds, as well as a new drug development cooperation. The document is a formal announcement of board decisions rather than the actual half-year report or financial statements. It is not a full interim report (IR) but a board/management information announcement about resolutions passed. Therefore, the appropriate classification is Board/Management Information (MANG). The document length is short and it contains voting results on board resolutions, consistent with MANG filings.
2016-08-17 Chinese
2016年半年度募集资金存放与使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is titled as a "2016 半年度募集资金存放与使用情况的专项报告" which translates to a "2016 Semi-Annual Special Report on the Deposit and Use of Raised Funds." It details the use and management of funds raised through various stock issuances, including initial public offering, additional issuance, and private placements. It includes detailed financial data on the raised funds, their storage, investment projects, and usage status as of June 30, 2016. The document references regulatory requirements from the China Securities Regulatory Commission and Shanghai Stock Exchange regarding the management and reporting of raised funds. The document is substantive, contains actual financial data, and is a specialized report on the use of capital raised by the company. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes. It is not an announcement of a report publication, nor a general regulatory filing. Therefore, the correct classification is CAP with high confidence.
2016-08-17 Chinese

Browse filings by year

26 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.